Liminatus Pharma Stock (NASDAQ:LIMN)

Financials Chart

Previous Close

$0.89

52W Range

$0.61 - $33.66

50D Avg

$1.31

200D Avg

$5.37

Market Cap

$26.42M

Avg Vol (3M)

$726.74K

Beta

0.36

Div Yield

-

LIMN Company Profile

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

May 01, 2025

Website

LIMN Performance

LIMN Financial Summary

	Dec 24
Revenue	-
Operating Income	$-405.00
Net Income	$-405.00
EBITDA	$-405.00
Basic EPS	$-4.05
Diluted EPS	$-4.05

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
DYAI	Dyadic International, Inc.
EVAX	Evaxion Biotech A/S
MURA	Mural Oncology plc
JSPR	Jasper Therapeutics, Inc.
BTAI	BioXcel Therapeutics, Inc.
SABS	SAB Biotherapeutics, Inc.
GBIO	Generation Bio Co.
ATHE	Alterity Therapeutics Limited